Solta Medical, Inc.
https://soltamedical.com.au/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Solta Medical, Inc.
IPO Update: Mid-Year Average Return Deceptively Positive In Down Market
The 14 biopharma firms that went public during the first half of the year generated a 25% average return, helped by an outlier whose value rose 585%. Excluding Belite Bio, the -18% return for the IPO class of 2022 is more representative of current market realities.
Bausch Hopes B+L Spin-Out Will 'Unlock' The Value Of Eye-Care Business
Bausch Health is paying down its debt with a $630m IPO for its Bausch + Lomb eyecare product business.
Bausch Investors Initially Pessimistic Following B+L Spinout
With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.
J.P. Morgan Day 3: First TCR Therapy On The Horizon, Asian Firms Make Their Mark
Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming, what the year could look like in deals and new updates from multiple Asian companies.
Company Information
- Industry
- Medical Devices
-
Medical Devices
- Laser
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice